No difference in retinal fluorescence after oral curcumin intake in amyloid-proven AD cases compared to controls

Jurre den Haan MD, PhD1  |  Frederique J. Hart de Ruyter MD1  |  Benjamin Lochocki PhD2  |  Maurice A.G.M. Kroon PharmD3  |  E. Marleen Kemper PharmD, PhD3  |  Charlotte E. Teunissen PhD4  |  Bart van Berckel MD, PhD5  |  Philip Scheltens MD, PhD1  |  Jeroen J. Hoozemans PhD6  |  Aleid van de Kreeke MD, PhD7  |  Frank D. Verbraak MD, PhD7  |  Johannes F. de Boer PhD2  |  Femke H. Bouwman MD, PhD1

1Amsterdam UMC, location VUmc, Alzheimer Center, Neurology, Amsterdam, The Netherlands
2VU Amsterdam, Department of Physics, LaserLaB, Amsterdam, The Netherlands
3Amsterdam UMC, location AMC, Department of Pharmacy and Clinical Pharmacology, Amsterdam, The Netherlands
4Amsterdam UMC, location VUmc, Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
5Amsterdam UMC, location VUmc, Department of Nuclear Medicine, Amsterdam, The Netherlands
6Amsterdam UMC, location VUmc, Department of Pathology, Amsterdam Neuroscience, Amsterdam, The Netherlands
7Amsterdam UMC, location VUmc, Ophthalmology Department, Amsterdam, The Netherlands

Correspondence
Femke H. Bouwman, MD, PhD, Alzheimer Center Amsterdam, Department of Neurology, Amsterdam UMC, Mailbox 7057, 1007 MB Amsterdam, The Netherlands.
Email: femke.bouwman@amsterdamumc.nl

Abstract

Introduction: Previous work has showed the in vivo presence of retinal amyloid in Alzheimer’s disease (AD) patients using curcumin. We aimed to replicate these findings in an amyloid biomarker–confirmed cohort.

Methods: Twenty-six patients with AD (age 66 [+9], Mini-Mental Status Examination [MMSE] ≥17) and 14 controls (age 71 [+12]) used one of three curcumin formulations: Longvida, Theracurmin, and Novasol. Plasma levels were determined and pre- and post-curcumin retinal fluorescence scans were assessed visually in all cases and quantitatively assessed in a subset.

Results: Visual assessment showed no difference between AD patients and controls for pre- and post-curcumin images. This was confirmed by quantitative analyses on a subset. Mean conjugated plasma curcumin levels were 198.7 nM (Longvida), 576.6 nM (Theracurmin), and 1605.8 nM (Novasol).

Discussion: We found no difference in retinal fluorescence between amyloid-confirmed AD cases and control participants, using Longvida and two additional curcumin formulations. Additional replication studies in amyloid-confirmed cohorts are needed to assess the diagnostic value of retinal fluorescence as an AD biomarker.

KEYWORDS
Alzheimer’s disease, amyloid, biomarker, curcumin, retina
1 | BACKGROUND

Alzheimer’s disease (AD) research over the last decades enabled clinicians to diagnose AD not only in the dementia end-stage but also in the prodromal and preclinical stages using biomarkers for amyloid, tau, and neurodegeneration.\(^1,2\) AD pathology starts 15 to 20 years before symptom onset and is reflected by a change of biomarkers in the preclinical stage.\(^1\) This time interval provides a window of opportunity for disease-modifying drugs to potentially halt disease progression toward the end stage of AD dementia.\(^3\) Because currently used biomarkers are time-consuming, expensive, and/or invasive, non-invasive easily accessible biomarkers are urgently needed to diagnose AD in the earliest stages, enabling timely selection of patients for trials and future medication.

The retina is an extension of the central nervous system and might provide such a biomarker. As such the retina is studied increasingly for manifestations of AD as potential non-invasive AD biomarkers. For example, retinal thinning, changes in retinal vasculature, and peripheral drusen have been described in patients with AD.\(^4-6\) More specifically related to AD pathology, three small studies reported visualization of retinal amyloid beta (A\(_\beta\)) deposits in vivo using curcumin, a polyphenol with fluorescent properties that binds to amyloid in post-mortem brain tissue.\(^7-9\) The presence of retinal amyloid beta deposits is, not unequivocally proven, however, since we and other groups could not confirm amyloid beta deposits in post-mortem retinal tissue.\(^10-14\) Moreover, curcumin is known for its low bioavailability, and although several commercially available formulations enhancing curcumin plasma levels are on the market, so far only one formulation (Longvida) has been reported to visualize retinal amyloid.\(^7\)

In the current study, we used three different curcumin formulations as labeling fluorophores in vivo. Using a targeted fluorescence approach, we aimed to visualize retinal amyloid in a well-characterized and amyloid biomarker–confirmed AD cohort.

2 | METHODS

2.1 | Participants

We enrolled 26 patients with AD (Mini-Mental Status Examination [MMSE] score ≥17) and 14 controls (MMSE ≥27) from two different cohorts—the Alzheimer Dementia Cohort (ADC) and the EMIF-AD PreclinAD study. All subjects underwent extensive screening according to a standardized protocol described elsewhere.\(^15,16\) All patients fulfilled National Institute on Aging—Alzheimer’s Association (NIA-AA) criteria of AD with amyloid biomarker confirmation through either cerebrospinal fluid (CSF) A\(\beta_{1-42}\) (A\(\beta_{42}\)) analysis or amyloid–positron emission tomography (PET).\(^1\) ADC controls had subjective cognitive decline, defined as cognitive complaints without objective cognitive impairment on neuropsychological exam, no signs of neurodegeneration on neuroimaging, and absence of AD pathology based on CSF biomarkers and/or amyloid-PET. Exclusion criteria for all participants were ophthalmological conditions interfering with retinal scan quality, for example, diabetic retinopathy, glaucoma, or moderate/intermediate age-related macular degeneration. In addition, we excluded subjects with ischemic stroke and/or mild to severe white matter hyperintensities on magnetic resonance imaging (MRI), operationalized as a Fazekas score > 2. We excluded two AD patients, one because of problems with eye fixation due to visuoperceptive dysfunction and one because of participation in a drug trial with disease-modifying drugs. We excluded two controls, one due to problems finishing the scan protocol because of dry eyes and one because of glaucoma. Three AD patients were lost to follow-up. This study was designed and conducted according to the Declaration of Helsinki and

RESEARCH IN CONTEXT

1. Systematic Review: We reviewed the literature using PubMed until July 2021 describing retinal amyloid in patients with Alzheimer’s disease (AD). Search terms included “AD,” “retina,” “eye,” “curcumin,” and “amyloid.” Three post-mortem studies described the presence of retinal amyloid, whereas four independent groups could not replicate these findings. Three small in vivo studies showed an increase of retinal hyperfluorescence after curcumin intake in AD cases compared to controls, interpreted as retinal amyloid.

2. Interpretation: To our knowledge this is the largest study to assess retinal fluorescence imaging in biomarker-proven AD cases and controls following oral curcumin administration. We found no differences in retinal fluorescence between diagnostic groups pre- and post-curcumin.

3. Future directions: Currently retinal fluorescence imaging after curcumin is insufficiently validated as an in vivo biomarker for AD. Additional replication studies in amyloid-confirmed cohorts are needed to assess the diagnostic value of retinal fluorescence as an AD biomarker.

HIGHLIGHTS

- It is hypothesized that retinal amyloid can be visualized after oral curcumin intake.
- We used two curcumin formulations, yielding higher plasma levels than Longvida.
- We included 26 Alzheimer’s disease (AD) patients and 14 controls with amyloid-biomarker confirmation.
- This is the largest amyloid-confirmed cohort for this purpose thus far.
- No difference in retinal fluorescence was found between AD patients and controls.
the study protocol was approved by the ethical committee of the VU University Medical Center. All patients gave their written informed consent in the presence of their caregivers.

2.2 | Amyloid biomarker assessment

Between 2016 and 2018, CSF concentrations of $A_\beta_{42}$, total tau, and tau phosphorlated at threonine 181 ($p$-tau$_{181}$) were measured using Innotest enzyme-linked immunosorbent assays (ELISAs; Fujirebio, Ghent, Belgium). Between 2018 and 2020, these CSF biomarkers were assessed using Elecsys $A_\beta_{1-42}$ CSF, Elecsys total-tau CSF, and Elecsys $p$-tau$_{181}$ CSF electrochemiluminescence immunoassays (Roche Diagnostics, Basel, Switzerland). For comparison, Innotest CSF values were converted using previously published conversion formulas.$^{17}$ A $p$-tau/$A_\beta_{42}$-ratio $\geq 0.020$ was considered an AD profile.$^{18}$

Amyloid-PET scanning was performed with $^{18}$F-Florbetaben (Neuracera), $^{18}$F-Florbetapir (Amyvid), or $^{18}$F-Flutemetamol (Vizamyl) tracers.$^{19} - 21$ An experienced nuclear physician (BvB) who completed training for all radiotracers visually assessed images of amyloid-PET scans as positive or negative.

2.3 | Ophthalmologic assessment

Subjects underwent the following general eye examination: best corrected visual acuity (VA), intraocular pressure (IOP) using non-contact tonometry, and slit-lamp examination of the anterior and posterior segments, followed by administration of tropicamide 0.5% to dilate the pupil for optimal retinal imaging. An experienced ophthalmologist (FDV) interpreted all examinations.

2.4 | Heidelberg scanning laser ophthalmoscope heidelberg retina angiograph imaging

Retinal fluorescence imaging was performed with a Heidelberg Engineering Spectralis Spectral Domain Scanning Laser Ophthalmoscope, at a 486 nm wavelength (blue autofluorescence) laser source to excite fluorescence, in combination with a long-pass 500 filter (high transmission in 498–760 nm and 800–835 nm). Optical resolution was 12 $\mu$m with a 55° lens, and 6 $\mu$m with a 30° lens. For each final image an average of 50 frames was used with a sensitivity $> 90$.

2.5 | Curcumin administration and timing of fluorescence imaging

Three different oral formulations of curcumin were used:

- Longvida Solid-Lipid Curcumin Particle (Verdure Sciences), was given in a dosage of 4000 mg per day for 10 consecutive days to 14 AD patients and 12 controls.$^7$ Here we used a 30° lens to acquire images in six regions of interest (ROIs) (central macula, superior, temporal, inferior, superior-temporal, and inferior-temporal) at baseline and 2 to 4 hours after the 10th day of curcumin intake (Figure 1A,B).

- Theracurmin (Theracurmin; Theravalue, Tokyo, Japan), was given in a dosage of 180 mg for five consecutive days to seven AD patients and two controls.$^{22,23}$ Here we acquired images using a 30° lens in three ROIs (central macula, optic nerve head [ONH], and temporal) at four different time points: (1) at baseline, (2) after 4 days of curcumin intake, (3) 1 hour after the fifth dose, and (4) 2 hours after the fifth dose (Figure 1A,B).

- Novasol (AQUANOVA AG, Darmstadt, Germany), was given in a dosage of 300 mg for four consecutive days and a final dose of 500 mg on day 5 to five AD patients.$^{24,25}$ With Novasol we acquired images using a 55° lens in six ROIs (central macula, superior, temporal, inferior, superior-temporal, and inferior-temporal) at baseline and 2 hours after the fifth dose (Figure 1A,B).

2.6 | Retinal fluorescence image analysis

Baseline and post-curcumin-administration images were assessed both visually and quantitatively. Visual assessment was performed by an experienced ophthalmologist, masked for diagnosis and curcumin treatment (FDV). Baseline and post-curcumin-administration images of AD patients were compared for the Novasol cohort and also between AD and control subjects for the Theracurmin and Longvida cohorts. To support the visual assessment, we used the Longvida cohort for quantitative analysis, allowing comparison to previous publications using Longvida as curcumin derivative. Images of the right eye with sufficient image quality (scans that were out of focus, had extensive shading, or extreme low/high contrast hampering co-registration were excluded) were assessed for quantitative analysis (Figure 1C). Retinal fluorescence imaging yielded 8-bit grayscale images sized 1536 $\times$ 1566 or 768 $\times$ 798 pixels with a resolution of 6 or 12 $\mu$m, respectively, per pixel. The non-normalized, uncompressed images were compared between time points using MATLAB 2020b (MathWorks). An image pair of two time points of similar ROIs were cropped to a size of 1430 $\times$ 1430 or 715 $\times$ 715 pixels to remove the manufacturer logo and blurry edges. In the case any image pair contained high-resolution images (1430 $\times$ 1430) the images were down-sampled to match the size of 715 $\times$ 715 pixels. Afterwards, both images were flat-field corrected to compensate for any illumination and shading effect. A registration algorithm (feature-based registration [SURF: Speeded-Up Robust Features] with affine transformation, allowing for rotation) was used to register matched images.$^{26}$ If an automatic match was not obtained, the software interrupted and allowed for manual picking of identical points of interest in both images and creating a registration match based on the user’s input (using the same registration algorithm). Registered images were cropped to a size of 512 $\times$ 512 pixels, ensuring that both images overlapped within the imaged field of view. Brightness histograms of both images were obtained and matched (using a cubic polynomial) to the histogram of the baseline image, resulting in images with similar contrast and overall brightness. We defined focal retinal hyperfluorescence by selecting areas of $\geq 4$
adjacent pixels that represented the 10% highest pixel value in the post-curcumin image. These hyperfluorescence spots were labeled, and their area and brightness measured. The same properties were measured in the baseline image, using the same spots (as identified in the post-curcumin image). Afterward, the brightness difference between each hyperfluorescence spot was calculated.

2.7 Curcuminoids plasma level analysis

Blood was drawn in heparinized tubes that were kept directly in aluminum foil on ice to avoid degradation by light and temperature. Within 30 minutes, plasma and serum were separated and plasma was stored at \(-80^\circ\text{C}\) in the Amsterdam UMC Biobank. High-performance liquid chromatography-tandem mass spectroscopy (HPLC-MS-MS) analysis was performed to measure different curcuminoids: curcumin, demethoxycurcumin, bisdemethoxycurcumin, and tetrahydrocurcumin. Each sample was treated, in duplicates, with and without \(\beta\)-glucuronidase, after which unconjugated and conjugated curcuminoids were quantified. Treatment with \(\beta\)-glucuronidase hydrolyzes the conjugated curcuminoids leading to an increase in unconjugated curcuminoids, whereas untreated samples were quantified on unconjugated curcumin at that point of time. Our validated method of analysis can be described, in short, as follows: Liquid-liquid extraction with tert butyl methyl ether (TBME) was used to extract the compounds from the plasma.\(^{27}\) The HPLC-MS/MS system consisted of an Ultimate 3000 autosampler and pump, both of Dionex, connected to a degasser from LC Packings. The autosampler, with a 100 \(\mu\text{L}\) sample loop, was coupled to a Sciex API4000 mass spectrometer. A total of 50 \(\mu\text{L}\) sample was injected, after which separation of the analytes was performed.
with an Agilent column 2.1 × 100 mm packed with material of Zorbax Extend 3.5 μm C-18. The flowrate was 0.200 μL/min and the dual gradient mobile phase consisted of A: ultra-purified H2O with 0.1% formic acid and B: MeOH 100%. The applied gradient profile started at 50:50 A:B and increased linearly to 95% B in 3.0 minutes. During 6 minutes a 5:95 A:B level was continued, after which it returned in 0.2 minutes to 50:50. Afterward, the system was equilibrated during 6 minutes at the starting level. Throughout the liquid-liquid extraction and HPLC-MS/MS the potential influence of light brought back to a minimum by working in a dark environment. Each analytical run included a set of freshly prepared calibration samples containing all compounds in the validated range of 2 nM to 400 nM. Each compound was validated with its own deuterated internal standard.

### 2.8 Statistical analysis

SPSS version 26.0 (IBM, Armonk, NY, USA) was used to assess group differences in demographics, curcumin data, and quantitative retinal fluorescence. Chi-square test was used for dichotomous variables, independent sample T-test was used for continuous variables that were normally distributed, and Mann-Whitney U test was used for non-normal distributed variables. Quantitative comparison of focal retinal hyperfluorescence between AD patients and controls was assessed by calculating the number of focal retinal hyperfluorescent pixels defined as a value in the top 10% value range at baseline and after curcumin, for all retinal regions of the right eye. Between-group differences were assessed using a Mann-Whitney U test. Significance level for all tests was set at 0.05.

### 3 RESULTS

Group demographics of AD and control cases are shown in Table 1, and Table S1 shows the data for each individual participant. The control group comprised more female participants. No differences were found for age between the AD and control group. As expected, and by design, we found significant group differences for MMSE as well as CSF and amyloid-PET biomarkers. Table 2 shows the demographics of the sub-group used for the quantitative analysis. No statistical group differences in age and sex were found.

#### 3.1 Qualitative and quantitative retinal fluorescence analysis

No scans were excluded for the qualitative analysis. The qualitative assessment of images pre- and post-curcumin intake by an experienced ophthalmologist (FDV) masked for the clinical diagnosis did not show differences in focal hyperfluorescence in the ROIs, for either AD patients (Longvida, Theracurmin, and Novasol) or controls (Longvida and Theracurmin)(Figure 2 and Figures S1 and S2).
FIGURE 2  Pre- and post-curcumin retinal fluorescence images for AD and control participants using Longvida pre- and post-curcumin retinal fluorescence images using blue auto fluorescence ($\lambda$ = 486 nm) in six retinal regions in a representative AD patient and control. Magnifications show incidental focal hyperfluorescence, both at baseline and after curcumin in AD and control participants. Abbreviations: AD, Alzheimer’s disease; I, inferior; M, macula; S, superior; T, temporal; TI, temporal-inferior; TS, temporal-superior.

TABLE 2  Demographics Longvida subgroup quantitative analysis

|          | AD      | CN      | P-value |
|----------|---------|---------|---------|
| Sex (F/M)| 6/8     | 7/4     | .302    |
| Age, mean (SD) | 71(9) | 73(11)  | .405    |
| MMSE, median (IQR) | 24(19–30) | 29(27–30) | <.001   |
| CSF Aβ, median (IQR) | 560(322–805) | 1198(641–1498) | .048    |
| CSF tau, median (IQR) | 295(108–551) | 247(136–364) | .683    |
| CSF p-tau, median (IQR) | 31(11–33) | 22(11–33) | .461    |
| Amyloid-PET (visual read): (positive/ negative) | 7/0 | 0/11 | <.001   |

Note: CSF data (presented as pg/mL) were available in eight AD cases and four controls. Amyloid-PET data (visual read) were available in 7 AD cases and 12 controls.

In this study we aimed to discriminate AD patients from controls with a targeted fluorescence approach of the retina using curcumin as fluorophore in a well-characterized AD biomarker-confirmed cohort. Using three different curcumin formulations, we did not find differences in focal retinal hyperfluorescence before or after curcumin intake between the diagnostic groups, despite an observed overall increase in retinal fluorescence after curcumin intake.

Our negative findings may be explained by a low intensity of the fluorescent signal resulting from (amyloid-bound) curcumin, insufficient binding of unconjugated curcumin to retinal amyloid, absence of retinal amyloid (in this subset of patients), or methodological limitations of our scanning and analysis methods.

Fluorescence of curcumin largely overlaps with autofluorescence of the retina. This might, therefore, mask subtle signals of curcumin fluorescence hypothesized to be the result of retinal amyloid (plaque) pathology, reported to be $\approx$5 to 20 $\mu$m. At present no data are available describing the magnitude of fluorescent signal that can be expected from retinal amyloid relative to retinal autofluorescence. On visual inspection we could identify a certain number of hyperfluorescent spots (Figure 3, zoom-ins); however, there was no difference

1605.8 nM ($\pm$ 524.6 nM) after Novasol (Figure 3). There were no differences in plasma levels between diagnostic groups ($P > .3$, data not shown).

4  DISCUSSION

In this study we aimed to discriminate AD patients from controls with a targeted fluorescence approach of the retina using curcumin as fluorophore in a well-characterized AD biomarker-confirmed cohort. Using three different curcumin formulations, we did not find differences in focal retinal hyperfluorescence before or after curcumin intake between the diagnostic groups, despite an observed overall increase in retinal fluorescence after curcumin intake.

Our negative findings may be explained by a low intensity of the fluorescent signal resulting from (amyloid-bound) curcumin, insufficient binding of unconjugated curcumin to retinal amyloid, absence of retinal amyloid (in this subset of patients), or methodological limitations of our scanning and analysis methods.

Fluorescence of curcumin largely overlaps with autofluorescence of the retina. This might, therefore, mask subtle signals of curcumin fluorescence hypothesized to be the result of retinal amyloid (plaque) pathology, reported to be $\approx$5 to 20 $\mu$m. At present no data are available describing the magnitude of fluorescent signal that can be expected from retinal amyloid relative to retinal autofluorescence. On visual inspection we could identify a certain number of hyperfluorescent spots (Figure 3, zoom-ins); however, there was no difference
between AD patients and controls in these spots, either in size or intensity, neither at baseline nor after curcumin intake. To increase sensitivity for weak retinal fluorescent signal possibly overlooked by visual inspection, we performed a quantitative analysis on a subset of participants (14 AD, 11 controls) who received Longvida and confirmed findings of the visual inspection.

The absence of a fluorescent signal after curcumin intake could also be explained by insufficient curcumin binding to retinal amyloid due to low plasma levels of unconjugated curcumin. After deconjugation using β-glucuronidase, we observed high blood levels of total curcumin, in line with previous studies. In contrast, Koronyo et al. found high levels of unconjugated curcumin (400 nM) without using β-glucuronidase. This could be attributed to their different analysis methods: (1) wider/broader calibration settings; (2) internal standards without deuterated forms and validated in mouse; and (3) acidification instead of freezing to stabilize samples.

Nevertheless, conjugated forms of curcumin are known to bind to amyloid as well following ex vivo application to post-mortem brain sections. And penetration of curcumin in the retina is suggested by our quantitative analysis, where a general increase in fluorescence was observed after curcumin intake (data not shown), implying that curcumin with the capacity to bind fibrillar amyloid reached the retina. Despite 3 to 4 times higher plasma levels of curcumin conjugates using Theracurmin and Novasol compared to Longvida in this study, we found no difference in focal retinal hyperfluorescence between AD patients and controls.

The lack of between-group differences in our study could also be explained by an absence of amyloid in the retina. The presence of (fibrillar) amyloid in the human retina is not unequivocally proven, as three labs showed positive staining with 6E10 and 12F4 antibodies interpreted as the presence of retinal amyloid plaques in post-mortem retinas, whereas others were unable to replicate these findings. Methodological heterogeneity in post-mortem study methods might account for these discrepancies. Replication studies and harmonization of study methods are needed to overcome these discrepancies before the presence of retinal amyloid in AD can undoubtedly be confirmed. This is one of the key goals of “The Eye as a Biomarker for AD” Personal Interest Area of the Alzheimer’s Association.

Three previous studies showed hyperfluorescence in AD cases after curcumin intake. Although these studies were of similar small sample size, AD biomarker confirmation was lacking, which is essential when relating retinal changes to AD, since other structures may cause changes in fluorescence as well. For example, retinal drusen, associated with macular degeneration, contains amyloid and other age-related deposits. This may account for the positive findings in Koronyo’s study, where AD patients had a mean age of 76 years compared to 53 years in controls. More work is needed to discriminate normal aging from pathological neurodegenerative changes in the retina underlying the observed changes in retinal fluorescence.

There are some limitations of this study, potentially explaining the negative findings. First, our scan timing might have been suboptimal for measuring curcumin bound to retinal amyloid resulting in impaired sensitivity. The optimal time point to measure retinal fluorescence is still to be determined. We based our scan timing on previously published pharmacokinetic curves of systemically available curcumin representing assumed peak levels of systemic curcumin, as has been shown to yield signal before. Second, the quantitative analysis could not
TABLE 3  Quantitative analysis

|                   | AD          | CN          | P-value |
|-------------------|-------------|-------------|---------|
| **Number of increased spots** |             |             |         |
| Macula            | 29.5        | 46.5        | .748    |
| Temporal          | 40.5        | 47.8        | .809    |
| Inferior          | 52.6        | 37.9        | .705    |
| Inferior-temporal | 33.3        | 28.0        | .403    |
| Superior          | 39.1        | 29.2        | .905    |
| Superior-temporal | 44.4        | 44.6        | 1.000   |

| **Number of decreased spots** |             |             |         |
| Macula            | 3.8         | 8.3         | .949    |
| Temporal          | 8.9         | 8.9         | .647    |
| Inferior          | 8.8         | 6.7         | .918    |
| Inferior-temporal | 5.2         | 4.7         | .926    |
| Superior          | 6.3         | 3.9         | .497    |
| Superior-temporal | 11.2        | 9.3         | .896    |

Note: Results of quantitative analyses of images obtained with 30-degree lens showing the number of spots with and increased or decreased pixel value after Longvida curcumin intake compared to baseline in all retinal regions for 14 AD and 12 control participants. Data are presented as mean and standard deviations. Group comparisons were made using a Mann-Whitney U test.

TABLE 4  Curcuminoids plasma levels

|                 | Longvida     | Theracurmin  | Novasol     |
|-----------------|--------------|--------------|-------------|
| Curcumin        | 75.1 (70.2)  | 321.80 (146.1)| 1108.40 (503.3)|
| Demethoxycurcumin| 55 (62.5)   | 19.49 (9.7)  | 58.72 (28.6) |
| Bisdemethoxycurcumin | 13.7 (12.1) | 0.66 (0.3)   | 3.23 (2.4)   |
| Tetrahydrocurcumin | 43.6 (44.9) | 234.70 (95.5)| 435.4 (73.8) |
| Total curcuminoids | 156.2(169.6) | 576.6 (211.1)| 1605.8 (524.6)|

Note: Plasma levels (mean ± SD) of different curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin, and tetrahydrocurcumin) and total curcuminoids after β-glucuronidase treatment in nanomolar (nM). Time points for serum level measurement after the start of curcumin intake were 10 days for Longvida and 5 days for Theracurmin and Novasol.

ACKNOWLEDGMENTS

We gratefully acknowledge financial support from Stichting Alzheimercentrum VUMC, Alzheimer Nederland, the Dutch Technology Foundation STW (grant number 13935), part of the Netherlands Organization for Scientific Research (NWO), and which is partly funded by the Ministry of Economic Affairs, ISAQ (grant number 14518).

CONFLICTS OF INTEREST

The research of C.T. is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 [MIRADE], and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer’s Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer’s Association. C.T. is recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and
Health–Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. C.T. has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly; and has performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, and Vivoryon. F.B. has a collaboration contract with Biogen, Optima Dx, and Roche. Payments are made to the institution of VUMC. F.B. is committee member of EAN and chairs the atypical AD PIA and the Eye as biomarker for AD PIA of ISTAART. P.S. is chair of the steering committee in NOVARTIS, member of DSMB GENENTECH, global PI phase 1 study AC IMMUNE, member advisory board AXON NEUROSCIENCE, global PI phase 2B study EIP PHARMA, PI phase 2B study COGRX, member advisory board GEMVAX, COGNOPTIX, and CORTEXZYME, member strategic innovation committee GREEN VALLEY, PI global phase 2B study Vivoryon, PI global phase 2A study TOYAMA/ FUJI FILM, PI global phase 1A study IONIS, personal fees from Life Science Partners Amsterdam, outside the submitted work. J.B. is supported for the current study by NWO (Foundation for scientific research in the Netherlands, similar to NIH and NSF) and Co-financing by Heidelberg engineering as part of the competitive research proposal, administered by the funding agency. Both these fundings are paid to institution. Besides this study J.B. received in the past 36 months research grants from Heidelberg, top-consortia voor kennis en innovatie (TKI), Nederlandse organisatie voor toegepast-natuurwetenschappelijk onderzoek (TNO), and LSHM paid to institution. Personal fees from royalties through former employer, Massachusetts general Hospital, for IP that has been licensed to Terumo, Heidelberg engineering and Spectrawave as well as fees for expert witness for a UK based law firm. He is program committee member for a number of conferences, unpaid. J.dH., B.L., F.H., M.K., M.K., B.B., J.H., A.K., and F.V. report no conflict of interest and have nothing to disclose. Author disclosures are available in the supporting information.

AUTHOR CONTRIBUTIONS
Jurre den Haan: Literature search, study design, data collection, data analysis, data interpretation, figures, writing-original draft, and verified data. Frederique Hart de Ruyter: Data collection, data analysis, data interpretation, writing-review and editing. Benjamin Lochocki: Image analysis, quantitative data analysis, data interpretation, writing-review and editing. Maurice A.G.M. Kroon: Data collection plasma analysis, data analysis, data interpretation, and writing-original draft. Marleen E. Kemper: Methodology plasma analysis, writing-review and editing, and supervision. Charlotte E. Teunissen: Biomarker data interpretation, writing-review and editing. Bart van Berckel: Biomarker data interpretation, writing-review and editing. Philip Scheltens: Funding acquisition, writing-review and editing. Jeroen J. Hoozemans: Data interpretation, writing-review and editing. Aleid Kreeke: Data collection. Frank D. Verbraak: Methodology, study design, image data collection, data analysis, data interpretation, writing-review and editing, and verified data. Johannes F. de Boer: Funding acquisition, methodology, study design, data interpretation, writing-review and editing, and verified data. Femke H. Bouwman: Funding acquisition, study design, data analysis, data interpretation, writing-original draft, and verified data.

REFERENCES
1. Jack CR, Bennett DA, Blennow K, et al. Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562.
2. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292.
3. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577-1590.
4. Alber J, Goldfarb D, Thompson LI, et al. Developing retinal biomarkers for the earliest stages of Alzheimer’s disease: what we know, what we don’t, and how to move forward. Alzheimers Dement. 2020;16(1):229-243.
5. Gupta VB, Chitranshi N, Den Haan J, et al. Retinal changes in Alzheimer’s disease- integrated prospects of imaging, functional and molecular advances. Prog Retin Eye Res. 2021;82:100899.
6. Snyder PJ, Alber J, Alt C, et al. Retinal imaging in Alzheimer’s and neurodegenerative diseases. Alzheimers Dement. 2021;17(1):103-111.
7. Korkony Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017;2(16):1-19.
8. Tadokoro K, Yamashita T, Kimura S, et al. Retinal amyloid imaging for screening Alzheimer’s disease. J Alzheimers Dis. 2021;83(2):927-934.
9. Ngolab J, Donohue M, Belsha A, et al. Feasibility study for detection of retinal amyloid in clinical trials: the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial. Alzheimers Dement (Amst). 2021;13(1):e12199.
10. Den Haan J, Morrema THJ, Verbraak FD, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun. 2018;6(1):147.
11. Jiang J, Wang H, Li W, Cao X, Li C. Amyloid plaques in retina for diagnosis in Alzheimer’s patients: a meta-analysis. Front Aging Neurosci. 2016;8:267.
12. Williams EA, Mcguone D, Frosch MP, Hyman BT, Laver N, Stemer-Rachamimov A. Absence of Alzheimer disease neuropathologic changes in eyes of subjects with Alzheimer disease. J Neuropathol Exp Neurol. 2017;76(5):376-383.
13. Ho C-Y, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer’s and Parkinson’s disease patients. Brain Pathol. 2014;24(1):25-32.
14. Schon C, Hoffmann NA, Ochs SM, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One. 2012;7(12):e53547.
15. Konijnenberg E. Carter SF, Ten Kate M, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther. 2018;10(1):75.
16. Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62(3):1091-1111.
17. Willemsen EAJ, Maurik IS, Tijms BM, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimers Dement (Amst). 2018;10:563-572.
18. Willemsen EAJ, Tijms BM, van Berckel BNMM, et al. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement (Amst). 2021;13(1):e12182.
19. Barthel H, Gertz H-J, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy
controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424-435.
20. Clark CM. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-283.
21. Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287-294.
22. Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. 2013;71(6):1521-1530.
23. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-665.
24. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014;58(3):516-527.
25. Kocher A, Bohner L, Schiborr C, Frank J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res. 2016;60(7):1555-1563.
26. Bay H, Tuytelaars T, Van Gool L. SURF: Speeded Up Robust Features. in Computer Vision – ECCV 2006. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006.
27. Kroon MAGvLv, Swart HWM, Kemper EL, Marleen E, van Tellingen O. A Validated Hplc-Ms/Ms Method for Simultaneously Analyzing Curcuminoids, Tetrahydrocurcumin and Piperine in Human Plasma, Urine or Feces. Available at SSRN: https://ssrn.com/abstract=4077493 or https://doi.org/10.2139/ssrn.4077493. SSRN, 2022.
28. Den Haan J, Morrema THJ, Rozemuller AJ, Bouwman FH, Hoozemans JJM. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: implications for in-vivo diagnostics. Acta Neuropathol Commun. 2018;6(1):75.
29. Grimaldi A, Pediconi N, Oieni F, et al. Neuroinflammatory processes, A1 astrocyte activation and protein aggregation in the retina of Alzheimer’s disease patients, possible biomarkers for early diagnosis. Front Neurosci. 2019;13:925.
30. Tsai Y, Lu B, Ljubimov AV, et al. Ocular changes in TgF344-AD rat model of Alzheimer’s disease. Invest Ophthalmol Vis Sci. 2014;55(1):523-534.
31. Luibl V. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest. 2006;116(2):378-385.
32. Bergen AA, Arya S, Koster C, et al. On the origin of proteins in human drusen: the meet, greet and stick hypothesis. Prog Retin Eye Res. 2019;70:55-84.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.